SuperworthAstrana Health ASTH
- Market cap
- $2.1B
- PE
- 45.7×
- 8y median 35.1×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.5×
- EV/EBIT
- 26.2×
- Revenue, 12 months
- $3.8B
- +59% on a year ago
- Net margin
- 1.1%
- Free cash flow yield
- 4.5%
Astrana Health trades at 45.7× trailing earnings, pricier than 65% of the last ten years. Revenue was $3.8B over the last twelve months, up 59% on a year earlier with a 1% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $348.2M+10% | $353M+20% | $404.4M+20% | $486.3M+40% | $478.7M+38% | $665.2M+88% | $620.4M+53% | $654.8M+35% | $956M+100% | $950.5M+43% | $965.1M+56% | $972.5M+49% | |
| Cost of revenue | $275.4M+14% | $314.1M+24% | $330.4M+14% | $412.8M+41% | $405.2M+47% | $614.7M+96% | $549.1M+66% | $576.8M+40% | $858.9M+112% | $855.5M+39% | $859.4M+57% | $868.5M+51% |
| Gross profit | $72.8M−5% | $39M−5% | $74M+55% | $73.5M+33% | $73.5M+1% | $50.5M+30% | $71.3M−4% | $78M+6% | $97.2M+32% | $95M+88% | $105.7M+48% | $104M+33% |
| SG&A | $29.4M+38% | $37.9M+55% | $38.7M+83% | $36M+50% | $37.8M+29% | $41.6M+10% | $43.9M+13% | $50.7M+41% | $62.4M+65% | $60.2M+45% | $61.7M+41% | $54.1M+7% |
| $39.1M−22% | −$3.9M | $30.1M+35% | $30.1M+11% | $28.4M−27% | $720K | $20.6M−32% | $20.3M−32% | $19.2M−32% | $18.4M+2455% | $28.5M+39% | $34.3M+69% | |
| Interest expense | $3.8M+56% | $5.4M+111% | $7.6M+132% | $8.6M+136% | $8.9M+134% | $8.1M+49% | $7.3M−4% | $7.4M−14% | $17.7M+100% | $17.5M+117% | $16.1M+120% | $16M+117% |
| Pre-tax income | $38M−8% | $924K−91% | $24M+24% | $31.9M+1% | $26.8M−30% | −$1.9M | $9.6M−60% | $16.8M−47% | $5.7M−79% | $7.5M | $19.7M+105% | $27.2M+62% |
| $10M−42% | $1M−91% | $7.1M+3% | $10M−28% | $7.8M−22% | $5.9M+478% | $3.4M−53% | $6.6M−34% | $4.6M−41% | $944K−84% | $6.6M+94% | $8.8M+33% | |
| Net income | $22.1M−5% | $12.4M | $14.8M+13% | $19.2M+46% | $16.1M−27% | −$7M | $6.7M−55% | $9.4M−51% | $373K−98% | $6M | $14.4M+116% | $19.7M+110% |
| $0.47−6% | $0.26 | $0.31+11% | $0.40+43% | $0.33−30% | −$0.15 | $0.14−55% | $0.19−53% | $0.01−97% | $0.12 | $0.29+107% | $0.40+111% | |
| 46.9M+2% | 47.1M+4% | 47.7M+2% | 48M+3% | 48.2M+3% | 47.8M+2% | 48.9M+2% | 49.5M+3% | 49.5M+3% | 49.5M+4% | 49.1M+0% | 49.8M+1% |
Revenue: Q1 FY11: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them. 52 periods, Q1 FY14 to Q2 FY26: not printed by the filing, worked out from its own lines.
SG&A: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Operating income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY11: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Net income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
EPS, diluted: 12 periods, Q1 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY11: share-days: the 6-month average less the second quarter's. 5 periods, Q4 FY11 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 7 periods, Q4 FY15 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Consulting Services nearest Astrana Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ASTHAstrana Health | $2.1B | 45.7× | 35.1× | 0.5× | +59% | 1.1% | |
| ICFIICF International | $1.7B | 19.5× | 23.2× | 0.9× | −8% | 4.9% | |
| HURNHuron Consulting | $3.1B | 29.3× | 25.9× | 1.7× | +14% | 6.4% | |
| EXPOExponent | $3.7B | 34.7× | 46.6× | 5.8× | +13% | 17.7% | |
| FCNFTI Consulting | $4.3B | 19.0× | 22.0× | 1.1× | +7% | 6.4% | |
| BWMNBowman Consulting | $742.5M | 107× | 106× | 1.4× | +14% | 1.4% | |
| GGenpact LTD | $6.9B | 12.1× | 21.6× | 1.3× | +7% | 11.1% | |
| BAHBooz Allen Hamilton | $9.4B | 12.3× | 21.5× | 0.8× | −7% | 7.0% | |
| HCKTHackett | $305.5M | 18.9× | 20.9× | 1.1× | −9% | 5.9% | |
| IIIInformation Services | $299.2M | 26.9× | 32.6× | 1.2× | +4% | 4.7% | |
| Peer median | $3.1B | 19.5× | 23.2× | 1.2× | +7% | 6.4% |
More on Astrana Health
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 17Consulting Services stocks with the fastest revenue growth
- #2of 12Consulting Services stocks with the fastest earnings growth
- #4of 21Consulting Services stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Consulting Services
- Sector
- Industrials
Valuation data, not investment advice. Prices as of .